Esaxerenone Protects against Diabetic Cardiomyopathy via Inhibition of the Chemokine and PI3K-Akt Signaling Pathway

Esaxerenone Protects against Diabetic Cardiomyopathy via Inhibition of the Chemokine and PI3K-Akt Signaling Pathway

(1) Background: Diabetic cardiomyopathy (DCM) is a unique form of cardiomyopathy that develops as a consequence of diabetes and significantly contributes to heart failure in patients. Esaxerenone, a selective non-steroidal mineralocorticoid receptor antagonist, has demonstrated potential in reducing...

Full description

Bibliographic Details
Main Authors: Ziyue Li, Huihui Zhang, Weihan Zheng, Zi Yan, Jiaxin Yang, Shiyu Li, Wenhua Huang
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Biomedicines
Subjects:
diabetic cardiomyopathy
esaxerenone
pharmacological mechanism
therapy
network pharmacology
Online Access:https://www.mdpi.com/2227-9059/11/12/3319

Internet

https://www.mdpi.com/2227-9059/11/12/3319

Similar Items